JP2008295444A5 - - Google Patents

Download PDF

Info

Publication number
JP2008295444A5
JP2008295444A5 JP2007265917A JP2007265917A JP2008295444A5 JP 2008295444 A5 JP2008295444 A5 JP 2008295444A5 JP 2007265917 A JP2007265917 A JP 2007265917A JP 2007265917 A JP2007265917 A JP 2007265917A JP 2008295444 A5 JP2008295444 A5 JP 2008295444A5
Authority
JP
Japan
Prior art keywords
seq
primer
antisense
base
primer set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007265917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008295444A (ja
JP4303303B2 (ja
Filing date
Publication date
Priority claimed from CA 2598893 external-priority patent/CA2598893C/en
Application filed filed Critical
Priority to JP2007265917A priority Critical patent/JP4303303B2/ja
Priority to US12/100,595 priority patent/US7605131B2/en
Publication of JP2008295444A publication Critical patent/JP2008295444A/ja
Publication of JP2008295444A5 publication Critical patent/JP2008295444A5/ja
Application granted granted Critical
Publication of JP4303303B2 publication Critical patent/JP4303303B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2007265917A 2006-10-11 2007-10-11 Ｅｍｌ４−ａｌｋ融合遺伝子 Active JP4303303B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007265917A JP4303303B2 (ja) 2006-10-11 2007-10-11 Ｅｍｌ４−ａｌｋ融合遺伝子
US12/100,595 US7605131B2 (en) 2006-10-11 2008-04-10 EML4-ALK fusion gene

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006277718 2006-10-11
JP2007120670 2007-05-01
CA 2598893 CA2598893C (en) 2006-10-11 2007-08-24 Eml4-alk fusion gene
JP2007265917A JP4303303B2 (ja) 2006-10-11 2007-10-11 Ｅｍｌ４−ａｌｋ融合遺伝子

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009035918A Division JP5172736B2 (ja) 2006-10-11 2009-02-18 Ｅｍｌ４−ａｌｋ融合遺伝子

Publications (3)

Publication Number Publication Date
JP2008295444A JP2008295444A (ja) 2008-12-11
JP2008295444A5 true JP2008295444A5 (enExample) 2009-02-12
JP4303303B2 JP4303303B2 (ja) 2009-07-29

Family

ID=39277176

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007265917A Active JP4303303B2 (ja) 2006-10-11 2007-10-11 Ｅｍｌ４−ａｌｋ融合遺伝子
JP2009035918A Active JP5172736B2 (ja) 2006-10-11 2009-02-18 Ｅｍｌ４−ａｌｋ融合遺伝子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009035918A Active JP5172736B2 (ja) 2006-10-11 2009-02-18 Ｅｍｌ４−ａｌｋ融合遺伝子

Country Status (7)

Country Link
US (7) US7728120B2 (enExample)
EP (1) EP2116553B1 (enExample)
JP (2) JP4303303B2 (enExample)
AT (1) ATE450547T1 (enExample)
CA (1) CA2598893C (enExample)
DE (1) DE602007003543D1 (enExample)
ES (2) ES2335368T3 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
PT2450437T (pt) * 2006-04-14 2017-08-25 Cell Signaling Technology Inc Defeitos de genes e cinase alk mutante em tumores sólidos humanos
ES2458497T3 (es) * 2006-04-14 2014-05-05 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
US8168383B2 (en) * 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
EP2255190A4 (en) * 2008-02-12 2011-05-04 Brigham & Womens Hospital FISH TEST FOR EML4-ALK FUSION IN LUNG CANCER
JP2009219728A (ja) * 2008-03-18 2009-10-01 Daito Giken:Kk 遊技台
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
AU2010248782B2 (en) * 2009-05-15 2015-06-11 Insight Genetics, Inc. Methods and compositions relating to fusions of ALK for diagnosing and treating cancer
WO2011043220A1 (ja) 2009-10-06 2011-04-14 富士レビオ株式会社 融合遺伝子の測定方法
US9175350B2 (en) 2009-12-22 2015-11-03 Quest Diagnostics Investments Incorporated EML4-ALK translocations in lung cancer
WO2011102507A1 (ja) * 2010-02-22 2011-08-25 富士レビオ株式会社 癌遺伝子の同定方法、癌遺伝子発現細胞の樹立方法、および癌遺伝子標的薬のスクリーニング方法
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
WO2011130635A2 (en) * 2010-04-16 2011-10-20 Response Genetics, Inc. Primers, probes, methods and kits for the detection of eml4-alk variants
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
CN103052386B (zh) 2010-08-20 2016-03-02 中外制药株式会社 含有四环化合物的组合物
EP2620497B1 (en) * 2010-09-02 2017-10-11 Kurume University Method for producing circular dna formed from single-molecule dna
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
JP5769952B2 (ja) * 2010-11-12 2015-08-26 株式会社Ｌｓｉメディエンス Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法
WO2012075318A2 (en) * 2010-12-01 2012-06-07 Cell Signaling Technology, Inc. Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
RS54189B1 (sr) * 2011-02-02 2015-12-31 Novartis Ag Postupci za korišćenje inibitora alk
WO2012139134A2 (en) * 2011-04-07 2012-10-11 Coferon, Inc. Methods of modulating oncogenic fusion proteins
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
JP6066209B2 (ja) * 2011-08-31 2017-01-25 学校法人 久留米大学 Ｄｎａ分子の環状化において単分子による環状化ｄｎａのみを選別する方法
PL2838998T3 (pl) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. EGFR i ROS1 w nowotworze
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US9084456B1 (en) * 2012-05-28 2015-07-21 Jack Zemer Linkage for jewelry components
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
CA2894220A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. Dot1l inhibitors for use in the treatment of leukemia
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US10705087B2 (en) 2013-07-26 2020-07-07 Japanese Foundation For Cancer Research Detection method for NTRK3 fusion
WO2015064620A1 (ja) * 2013-10-29 2015-05-07 公益財団法人がん研究会 新規融合体及びその検出法
JPWO2015064621A1 (ja) * 2013-10-29 2017-03-09 公益財団法人がん研究会 新規融合体及びその検出法
WO2015111716A1 (ja) 2014-01-24 2015-07-30 公益財団法人がん研究会 新規融合体及びその検出法
TWI831128B (zh) 2014-04-25 2024-02-01 日商中外製藥股份有限公司 以高用量含有４環性化合物的製劑
JP6873698B2 (ja) 2014-04-25 2021-05-19 中外製薬株式会社 ４環性化合物の新規結晶
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
EP2990493B1 (en) 2014-09-01 2017-05-24 ARKRAY, Inc. Primer reagent for amplifying alk fusion gene, alk fusion gene amplification reagent kit including the same, and alk fusion gene amplification method and alk fusion gene analysis method using the same
JP7015171B2 (ja) 2016-01-15 2022-02-02 公益財団法人がん研究会 新規融合体及びその検出法
JP6740172B2 (ja) * 2017-05-02 2020-08-12 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
WO2020006314A1 (en) * 2018-06-27 2020-01-02 City Of Hope Modification of small rnas for therapeutic uses
BR112020025499A2 (pt) 2018-06-29 2021-03-09 Chugai Seiyaku Kabushiki Kaisha Composição farmacêutica que compreende agente básico pouco solúvel
JP7385191B2 (ja) * 2019-08-30 2023-11-22 学校法人同志社 Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
JP2020156481A (ja) * 2020-04-06 2020-10-01 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
JP7849382B2 (ja) 2021-10-28 2026-04-21 中外製薬株式会社 シロップ剤
AU2023304031A1 (en) 2022-07-04 2025-02-06 Chugai Seiyaku Kabushiki Kaisha Combination drug
TW202425998A (zh) 2022-08-30 2024-07-01 日商中外製藥股份有限公司 併用醫藥

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716613B1 (en) 1999-11-11 2004-04-06 Yamanouchi Pharmaceutical Co., Ltd. Metalloprotease having aggrecanase activity
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
PT1660458E (pt) 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
JP2008502595A (ja) 2004-03-31 2008-01-31 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼモジュレータおよびその使用方法
ES2458497T3 (es) 2006-04-14 2014-05-05 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物

Similar Documents

Publication Publication Date Title
JP2008295444A5 (enExample)
US12534754B2 (en) Attenuators
JP2019196400A5 (enExample)
US11293048B2 (en) Attenuators
JP2003524416A5 (enExample)
JP2008532477A5 (enExample)
JP2008535489A5 (enExample)
JP2006512928A5 (enExample)
JP2008535509A5 (enExample)
JP2012514451A5 (enExample)
JP2007075118A5 (enExample)
JP2006518186A5 (enExample)
WO2006029184A3 (en) Genes useful for diagnosing and monitoring inflammation related disorders
JP2010035552A5 (enExample)
JP2005511023A5 (enExample)
JP4235645B2 (ja) 呼吸器疾患と関連した１０種のバクテリアに特異的なプライマーセット及びプローブオリゴヌクレオチド
JP2017521654A5 (enExample)
JP2004523211A5 (enExample)
JP2004519219A5 (enExample)
KR101531296B1 (ko) Streptococcus iniae의 병원성 판별용 유전자 마커 및 펩티드핵산을 이용한 병원성 결정 마커 검사키트
JP4934679B2 (ja) ９種の呼吸器疾患と関連するバクテリア種を特異的に検出するためのプライマー、プローブ、マイクロアレイおよびその方法
JP2006501465A5 (enExample)
JP2007513601A5 (enExample)
JP2014003946A5 (enExample)
JP2010136719A5 (enExample)